Evidence map›Paper›PMID 36657098›Full record

ArticleJCO oncology practice2023

Understanding the Role of Urology Practice Organization and Racial Composition in Prostate Cancer Treatment Disparities.

Nnenaya Agochukwu-Mmonu, Yongmei Qin, Samuel Kaufman, Mary Oerline, Randy Vince, Danil Makarov, Megan V Caram, Christina Chapman, Joseph Ravenell, Brent K Hollenbeck and 1 more

Open access · greenAbstract read
In one paragraph

Article in JCO oncology practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Nnenaya Agochukwu-MmonuDepartment of Urology, New York University Medical Center, New York, NY.ORCID 0000-0003-4620-8897
Yongmei QinDepartment of Urology, University of Michigan, Ann Arbor, MI.
Samuel KaufmanDepartment of Urology, University of Michigan, Ann Arbor, MI.
Mary OerlineDepartment of Urology, University of Michigan, Ann Arbor, MI.
Randy VinceDepartment of Urology, University of Michigan, Ann Arbor, MI.ORCID 0000-0002-7779-473X
Danil MakarovDepartment of Urology, New York University Medical Center, New York, NY.
Megan V CaramDepartment of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI.ORCID 0000-0003-1597-5428
Christina ChapmanDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI.
Joseph RavenellDepartment of Population Health, New York University Medical Center, New York, NY.ORCID 0000-0001-7024-3460
Brent K HollenbeckDepartment of Urology, University of Michigan, Ann Arbor, MI.
Ted A SkolarusDepartment of Urology, University of Michigan, Ann Arbor, MI.
University of Michigan · USColumbia University Irving Medical Center · US

Funding

De-implementation of low value castration for men with prostate cancerR37CA222885 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SAINI, SAMEER DEV, SKOLARUS, TED ALBERT · 2018 to 2023
$3.6M
Impact of urologist practice organization and health policy on prostate cancer treatment, overtreatment and spendingR01HS025707 · AHRQ · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HOLLENBECK, BRENT K., SHAHINIAN, VAHAKN B · 2017 to 2021
$1.7M
Refining castration use for recurrent prostate cancerR01CA242559 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SKOLARUS, TED ALBERT, TSODIKOV, ALEXANDER · 2020 to 2023
$1.4M
AHRQ HHS R01 HS025707NCI NIH HHS R01 CA242559NCI NIH HHS R37 CA222885
6 · The paper itself

Abstract

purposeBlack men have a higher risk of prostate cancer diagnosis and mortality but are less likely to receive definitive treatment. The impact of structural aspects on treatment is unknown but may lead to actionable insights to mitigate disparities. We sought to examine the associations between urology practice organization and racial composition and treatment patterns for Medicare beneficiaries with incident prostate cancer.

methodsUsing a 20% sample of national Medicare data, we identified beneficiaries diagnosed with prostate cancer between January 2010 and December 2015 and followed them through 2016. We linked urologists to their practices with tax identification numbers. We then linked patients to practices on the basis of their primary urologist. We grouped practices into quartiles on the basis of their proportion of Black patients. We used multilevel mixed-effects models to identify treatment associations.

resultsWe identified 54,443 patients with incident prostate cancer associated with 4,194 practices. Most patients were White (87%), and 9% were Black. We found wide variation in racial practice composition and practice segregation. Patients in practices with the highest proportion of Black patients had the lowest socioeconomic status (43.1%), highest comorbidity (9.9% with comorbidity score ≥ 3), and earlier age at prostate cancer diagnosis (33.5% age 66-69 years;

conclusionDespite Medicare coverage, we found less definitive treatment among Black beneficiaries consistent with ongoing prostate cancer treatment disparities. Our findings are reflective of the adverse effects of practice segregation and structural racism, highlighting the need for multilevel interventions.

Indexed as

Prostatic NeoplasmsUrologyAgedHumansMaleMedicareUnited StatesWhite

Identifiers

PMID36657098
PMCPMC10414720
OpenAlexW4317495285

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.